USC researchers have tracked down two Zika proteins potentially responsible for thousands of microcephaly cases in Brazil and elsewhere -- taking one small step toward preventing Zika-infected mothers from birthing babies with abnormally small heads.
Tuberculosis (TB) is a leading killer of people with HIV, and providing therapy for both illnesses simultaneously saves lives - according to new guidelines on the treatment of drug-susceptible TB developed jointly by the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA). Treatment of TB in the presence of HIV infection is one of several special situations addressed in the new guidelines, published today in the journal Clinical Infectious Diseases.
Coherus BioSciences, Inc. reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira®) biosimilar candidate. This study met its primary endpoint demonstrating similarity between CHS-1420 and Humira with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index (PASI-75) at Week 12.
Gaumard Scientific Company announced the launch of OMNI 2, a touch-screen wireless interface that transforms training with value-priced simulators and skills trainers into an easy, intuitive tap-and-go experience.
The parasites responsible for malaria and toxoplasmosis depend on mechanisms inherited from the plant world. This is what a team of researchers from CNRS and the University of Melbourne has shown. They have just published two studies in Cell Microbiology and PLOS Pathogens. This discovery is a major advance for the development of new therapeutic targets for these parasites, which have such substantial public health consequences.
The growing use of biologics, drugs with newer mechanisms of action, and combination therapies are trending in the global rheumatoid arthritis (RA) market. BCC Research reveals in its new report that the biosimilars market should grow at a torrential five-year (2015-2020) compound annual growth rate (CAGR) of 71%.
Rheumatoid arthritis is a chronic inflammatory disease characterized by progressive joint damage, disability and systemic complications. The goal of treatment in RA is to achieve clinical remission. When remission, defined as the absence of signs and symptoms of inflammation, is unattainable, the target of treatment is to lower disease activity, particularly in patients with established RA. This report provides perspective on drugs and therapies used in the management of RA.
The global market for therapies for RA is expected to grow from USD 19.9 billion in 2015 to nearly USD 21.3 billion by 2020, reflecting a five-year CAGR of 1.3%.As a therapeutic class, anti-interleukin biologics should grow from nearly USD 1.2 billion in 2015 to USD 1.5 billion in 2020 on a five-year CAGR of 4.4%. Biosimilars as a therapeutic class should reach nearly USD 5.4 billion in 2020 on a five-year CAGR of 71.0%, up from an anticipated USD 368 million in 2015.
The market for RA treatments in the seven major markets (U.S., France, Italy, Germany, Spain, U.K., and Japan) is expected to reach USD 16.3 billion and USD 17.2 billion in 2015 and 2020, respectively, reflecting a five-year CAGR of approximately 1%. The genericization and introduction of biosimilars for major products such as etanercept, infliximab and rituximab will impact market growth.
The market in the rest of the world (RoW), including India and China, should total USD 3.6 billion and USD 4.1 billion in 2015 and 2020, respectively, growing at a five-year CAGR of about 2.5%. The introduction of cheaper biosimilars and Janus kinase inhibitors (JAKs) will drive market growth.
The biosimilars market will witness incredible growth both in the RoW and globally. Their robust adoption is expected in the seven major markets, where healthcare providers are pushing for more affordable options to the high cost of biologics therapy, particularly for chronic immunological diseases.
"Worldwide, the value of the biosimilars market will grow from about USD 174 million in 2014 to almost USD 5.4 billion in 2020 due to the introduction of biosimilars," says BCC Research analyst Geeta Ogra Bedi. "Presently, a growing number of biosimilars are in the late stage of clinical development. Although biosimilars don't promise the kind of cost savings generated by their small-molecule counterparts, they still possess the ability to yield significant cost savings."
All animals begin life as a single cell from which arise the many different cell types, such as heart, lung, blood, etc., that are specific to that type of animal. However, once the process of cell differentiation has led to many different tissues, each organism has a new, opposite imperative – keeping new cells in each type of tissue the same as their brethren. Cancers arise in a tissue when a cell becomes different from its neighbors and thus represent a failure to maintain this critical uniformity.
People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report. While bNAbs cannot completely clear HIV infections in people who have already acquired the virus, many scientists believe a successful preventive HIV vaccine must induce bNAbs. The new findings indicate that bNAb production may be associated with specific variations in individual immune functions that may be triggered by unchecked HIV infection. Defining how to safely replicate these attributes in HIV-uninfected vaccine recipients may lead to better designed experimental vaccines to protect against HIV. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Scientists at The University of Nottingham have demonstrated for the first time that it is possible to selectively sequence fragments of DNA in real time, greatly reducing the time needed to analyse biological samples.
If Dr. Kalipada Pahan's research pans out, the standard advice for failing students might one day be: Study harder and eat your cinnamon!
Pahan a researcher at Rush University and the Jesse Brown Veterans Affairs Medical Center in Chicago, has found that cinnamon turns poor learners into good ones--among mice, that is. He hopes the same will hold true for people.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
